News & Press Releases

26 September 2016

ORYZON Closes € 5.3 Million (6 M USD) in additional Debt Financing

14 September 2016

ORYZON Selected as one of the Finalist for the 7th Annual Most Innovative EU Biotech SME Award

12 September 2016

Oryzon to Present ORY-2001 Preclinical efficacy data in Multiple Sclerosis animal model at ECTRIMS-2016 Annual Meeting

1 September 2016

Oryzon Genomics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference and at BioPharm America 2016

8 August 2016

ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2016

27 July 2016

Oryzon Initiates Multiple Ascending Dose Cohorts In ORY-2001 Phase 1 Clinical Trial

5 July 2016

Oryzon nominates ORY-3001, a specific LSD1 inhibitor, next drug candidate to enter preclinical development in non-oncological indications

6 June 2016

ORYZON to Present at the JMP Securities Life Sciences Conference on June 22nd, 2016

2 June 2016

EpigenomicsNet features Oryzon CSO Tamara Maes on Epigenetic drug development

18 May 2016

ORYZON to extend its R&D collaboration on ORY-1001 until March 2017

News